PEPG_OUT_1 [2025-04-02 19:56:42 -0400] 2048 Bytes | 584 tokens | Cum: 584 tkns (7.30% of 8k)
==========================================================================

Turbo, you got one job - predict the hottest stocks of the day -- before everyone else does! Ha! So today we're looking at PepGen (PEPG) which is at 1.54 up from 1.31. So, I pulled together a bunch of data for you to look over real fast. It's still early, 7:56:41 PM on Wed Apr 02, 2025 -0400. So, what's the verdict? You're the expert!

--- COMPANY PROFILE ---
Company: PepGen (PEPG)
IPO: IPO date unknown
Shares Outstanding: 32,689,999
Industry: PHARMACEUTICAL PREPARATIONS
Exchange: XNAS

Here's the first list of news for PepGen:

C1 - Today 04:05PM - PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference
C2 - Mar-31-25 04:05PM - PepGen Announces Appointment of Two New Directors to its Board
C3 - Mar-28-25 09:00AM - RNA Biotechs: Current State And Outlook
C4 - Mar-26-25 10:17AM - The Risk/Reward Of Avidity Biosciences And Its 2 Promising Programs
C5 - Mar-10-25 04:05PM - PepGen Announces Presentations at the 2025 Muscular Dystrophy Association Clinical & Scientific Conference
C6 - Mar-05-25 06:32AM - PepGen pauses Phase II DMD trial to review safety data
C7 - Mar-04-25 08:05AM - PepGen to Participate in Upcoming Investor Conferences
C8 - Mar-04-25 08:05AM 08:00AM - PepGen Announces Update to Phase 2 CONNECT2-EDO51 Study in Patients with DMD

ONLY 3 RULES for AI:
==============
1) I am a document retrieval system. You are the analyst-investigator.
2) You can request items from my lists to get more info on PepGen (PEPG)
3) AFTER requesting and reading News and SEC filings you'll write a summary, set a score, high price target and headline.
Now, your response should be only 2 or 3 chars. You can say ex., C1, C2, etc., or NEX
The NEX command delivers the NEXt list of News/SEC/Metrics
There are several more lists that use our unified document retrieval system in subsequent prompts.
Your predictons will be compared to reality to rate your accuracy. Try to predict accurately. GOOD LUCK!
Please request a document, read, summarize and score. Say something like "C1".

PEPG_OUT_3 [2025-04-02 19:56:49 -0400] 1102 Bytes | 337 tokens | Cum: 923 tkns (11.54% of 8k)
==========================================================================

Showing C6 (chunk 1 of 5): C6:
**PepGen pauses Phase II DMD trial to review safety data**
Date: Mar-05-25 06:32AM
Source: (Clinical Trials Arena)
URL: https://finance.yahoo.com/m/b1db5fca-a055-3016-ace1-734e41c6948a/pepgen-pauses-phase-ii-dmd.html

PepGen is pausing the initiation of a new Phase II Duchenne muscular dystrophy (DMD) study as it awaits data from an ongoing Phase II trial.

The US-based biotech said it made the voluntary decision to pause the Phase II CONNECT2-EDO51 trial (NCT06833931) of PGN-EDO51 until it has properly reviewed data from the 10mg cohort in the ongoing Phase II CONNECT1-EDO51 study (NCT06079736).

On the Nasdaq market, PepGen’s stock dropped 18% on the news, from a market close of $2.18 on 3 March to a close of $2.28 on 4 March.

PepGen president Dr James McArthur said: “This will allow us to gather additional safety data, assess the impact of this dose of PGN-EDO51 on dystrophin lev

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PEPG_OUT_5 [2025-04-02 19:56:50 -0400] 981 Bytes | 297 tokens | Cum: 1293 tkns (16.16% of 8k)
==========================================================================

We present this news so you can catch the big movers from recently breaking news.
Here's a list of news articles you can literally read just by asking.
Usually the first item is the most important.

A1 - 2025-04-02T20:13:52Z - PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference...
A2 - 2025-03-31T20:20:44Z - PepGen (PEPG) Appoints Lisa Wyman and Mitchell H. Finer to its Board...
A3 - 2025-03-30T12:00:00Z - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG |...
A4 - 2025-03-30T12:24:03Z - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG B...
A5 - 2025-03-26T12:26:10Z - INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of PepGen Inc - PEPG B...

Request an article by its reference number. (Ex., "A1" gets the first item)
You may also say NEX to go to the next listing.
Response to this prompt limited to 3 chars.

PEPG_OUT_7 [2025-04-02 19:56:54 -0400] 1098 Bytes | 295 tokens | Cum: 1590 tkns (19.88% of 8k)
==========================================================================

Showing A1 (chunk 1 of 2): A1:
**PepGen to Present at the 24th Annual Needham Virtual Healthcare Conference**Date: 2025-04-02Source: {'uri': 'wallstreet-online.de', 'dataType': 'news', 'title': 'wallstreet:online'}URL: https://www.wallstreet-online.de/nachricht/19185731-pepgen-to-present-at-the-24th-annual-needham-virtual-healthcare-conferencePepGen Inc. (Nasdaq: PEPG), a clinical-stage biotechnology company advancing the next generation of oligonucleotide therapies with the goal of transforming the treatment of severe neuromuscular and neurological diseases, today announced that James McArthur, PhD, President and CEO of PepGen, will present at the 24th Annual Needham Virtual Healthcare Conference on Wednesday, April 9, 2025 at 1:30pm ET.

A webcast of the corporate presentation will be available on the "Events & Presentations" page within the Investors section of the PepGen website at https://investors.pepgen.com

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PEPG_OUT_9 [2025-04-02 19:56:55 -0400] 935 Bytes | 294 tokens | Cum: 1971 tkns (24.64% of 8k)
==========================================================================

This is our final list of news.
News AI can literally read just by asking.
Don't miss the breaking news!

B1 - 2024-08-13T20:00:00Z - PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings
B2 - 2024-05-14T20:02:00Z - PepGen Reports First Quarter 2024 Financial Results and Recent Corporate Highlights
B3 - 2024-04-25T14:00:00Z - Best Momentum Stocks to Buy for April 25th
B4 - 2024-04-10T12:11:19Z - Insiders Buying GameStop And 2 Other Stocks
B5 - 2024-03-13T20:05:00Z - PepGen to Participate in Upcoming Investor Conferences
B6 - 2024-03-13T11:00:00Z - PepGen Receives U.S. FDA Orphan Drug and Rare Pediatric Disease Designations for PGN-EDO51 for the Treatment of Duchenne Muscular Dystrophy

Request an article by its reference number. (Ex., "B1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PEPG_OUT_11 [2025-04-02 19:56:59 -0400] 793 Bytes | 241 tokens | Cum: 2214 tkns (27.68% of 8k)
==========================================================================

Showing B1 (chunk 1 of 1): B1:
**PepGen Inc. (PEPG) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings**Date: Unknown DateSource: Unknown SourceURL: https://www.globenewswire.com/news-release/2024/08/13/2929584/9788/en/PepGen-Inc-PEPG-Investigation-Bronstein-Gewirtz-Grossman-LLC-Encourages-Investors-to-Seek-Compensation-for-Alleged-Wrongdoings.htmlPepGen Inc. (PEPG) stock dropped over 45% after the company released data from its ongoing Phase 2 trial. Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of PepGen investors.

--> You can ask for 1) More of this item with: MOR, 2) the NEXt section with: NEX, or 3) a different item by it's handle (ex. C3, S2) (only 3 chars don't summarize yet)

PEPG_OUT_13 [2025-04-02 19:56:59 -0400] 238 Bytes | 59 tokens | Cum: 2348 tkns (29.35% of 8k)
==========================================================================

This is our list of SEC filings.
If empty, the search returned no recent filings.

Request filing by its reference number. (Ex., "S1" gets the first item)
You can say NEX to go to the next listing.
Response limited to 3 chars.

PEPG_OUT_15 [2025-04-02 19:57:07 -0400] 6658 Bytes | 1871 tokens | Cum: 4222 tkns (52.78% of 8k)
==========================================================================

This is our set of metrics.
Please analyze the numbers.

+-------------------+-----------------------+-------------------------+----------------------+
| Volume: 219,082 | Perf Month: -35.96% | Option/Short: Yes / Yes | Sales Y/Y TTM: - |
+-------------------+-----------------------+-------------------------+----------------------+
| Avg Volume: 2.87M | Perf Quarter: -61.88% | Short Float: 10.48% | ROE: -79.26% |
+-------------------+-----------------------+-------------------------+----------------------+
| Rel Volume: 0.08 | Index: RUT | Short Ratio: 1.00 | ROI: -67.06% |
+-------------------+-----------------------+-------------------------+----------------------+
| RSI (14): 40.93 | Market Cap: 47.73M | Short Interest: 2.86M | Sales Surprise: - |
+-------------------+-----------------------+-------------------------+----------------------+
| ATR (14): 0.28 | Shs Outstand: 32.62M | Beta: 1.42 | EPS Surprise: 16.42% |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA20: -24.50% | Shs Float: 27.27M | Sales Q/Q: - | P/E: - |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA50: -19.06% | Inst Own: 85.67% | Sales past 5Y: 0.00% | Earnings: Feb 24 BMO |
+-------------------+-----------------------+-------------------------+----------------------+
| SMA200: -79.88% | Insider Own: 16.57% | Employees: 81 | |
+-------------------+-----------------------+-------------------------+----------------------+
| Perf Week: -7.01% | Insider Trans: -0.05% | Debt/Eq: 0.16 | |
+-------------------+-----------------------+-------------------------+----------------------+

The next section covers any insider trading.
If this section may be blank due to no recent filings.

No transactions recorded.

No transactions recorded.

Inside Trans: PepGen Inc. (PEPG) by Wyman Lisa (Unknown Title) on 2025-03-27
- Stock Option (Right to Buy): 26000 shares at $0 (D)

Inside Trans: PepGen Inc. (PEPG) by Finer Mitchell H. (Unknown Title) on 2025-03-27
- Stock Option (Right to Buy): 26000 shares at $0 (D)

Inside Trans: PepGen Inc. (PEPG) by McArthur James G (President and CEO) on 2025-03-03
- Common Stock: 60719 shares at $0 (D)
- Stock Option (Right to Buy): 271875 shares at $0 (D)

Inside Trans: PepGen Inc. (PEPG) by STRECK PAUL (EVP, Head of R&D) on 2025-03-03
- Common Stock: 19430 shares at $0 (D)
- Stock Option (Right to Buy): 87000 shares at $0 (D)

Inside Trans: PepGen Inc. (PEPG) by Donnelly Noel (Chief Financial Officer) on 2025-03-03
- Common Stock: 23283 shares at $0 (D)
- Stock Option (Right to Buy): 104250 shares at $0 (D)

Inside Trans: PepGen Inc. (PEPG) by DeLena Mary Beth (General Counsel) on 2025-03-03
- Common Stock: 13400 shares at $0 (D)
- Stock Option (Right to Buy): 60000 shares at $0 (D)

Inside Trans: PepGen Inc. (PEPG) by Donnelly Noel (Chief Financial Officer) on 2025-02-24
- Common Stock: 3200 shares at $0 (D)
- Common Stock: 1527 shares at $1.68 (D) Footnote: Represents shares automatically sold by the Company on behalf of the Reporting Person pursuant to a mandatory sell-to-cover provision in the award agreement required to cover minimum statutory tax withholding obligations that became due upon the vesting and settlement of the PSUs reported in this form. The mandatory sale of the Reporting Person's shares was provided for in a PSU agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

Inside Trans: PepGen Inc. (PEPG) by DeLena Mary Beth (General Counsel) on 2025-02-24
- Common Stock: 3000 shares at $0 (D)
- Common Stock: 1432 shares at $1.68 (D) Footnote: Represents shares automatically sold by the Reporting Person to satisfy tax withholding obligations in connection with the vesting of performance-based restricted stock units awarded to the Reporting Person on February 24, 2025. The automatic sale of the Reporting Person's shares is provided for in a restricted stock unit agreement constituting a "binding contract" consistent with the affirmative defense to liability under Rule 10b5-1 and the sale does not represent a discretionary trade by the Reporting Person.

[Company Financial Summary]
[Company Details]
Name: N/A
Market Cap: N/A
Shares Outstanding: N/A
Sector: N/A

[Financial Statements - Latest Quarter]
Total Assets: N/A
Total Liabilities: N/A
Total Equity: N/A
Revenue (Quarter): {'value': 0, 'unit': 'USD', 'label': 'Revenues', 'order': 100}
Net Income: {'value': -89981000.0, 'unit': 'USD', 'label': 'Net Income/Loss', 'order': 3200}
Earnings Per Share (EPS): N/A

[Price Metrics - Last 30 Days]
Latest Close: 1.46
Average Volume: 565331.96
30-Day High: 2.81
30-Day Low: 1.31

[Detailed Financials: TTM 2024]
- Total Assets: $150,883,000.0
- Total Liabilities: $32,263,000.0
- Total Equity: $118,620,000.0
- Current Assets: $123,761,000.0
- Current Liabilities: $16,696,000.0

[Income Statement: TTM 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.85

[Cash Flow Statement: TTM 2024]
- Net Cash Flow: $-31,291,000.0

[Detailed Financials: FY 2024]
- Total Assets: $150,883,000.0
- Total Liabilities: $32,263,000.0
- Total Equity: $118,620,000.0
- Current Assets: $123,761,000.0
- Current Liabilities: $16,696,000.0

[Income Statement: FY 2024]
- Revenue: $0.00
- Net Income: N/A
- Gross Profit: N/A
- Operating Income: N/A
- Earnings Per Share (EPS): -2.85

[Cash Flow Statement: FY 2024]
- Net Cash Flow: $-31,291,000.0
==== END OF FINANCIAL REPORT ====

You are now requested to make a summary analysis.
Save explaining why you didn't have enough information for the final survey.

Now, complete this report with the following:

1) Brief Summary: explain your findings in succinct wording.
2) MARKET_SCORE: If you calculate a 92% likelihood of an upward moves, say: MARKET_SCORE[92]
3) PRICE_TARGET: If you think the high today will be 50% higher, add to the price.
Eg., If the current price is $5.00, add 50%. Thus, PRICE_TARGET[$7.50] -- It should be at or above the current price.
4) Provide a thought-provoking take, 6-10 words, to use for the headline of this news story.
Like this: AI_RPT_HEADLINE: [6-12 words headline for news story, distilled from summary]

1) Brief Summary, 2) MARKET_SCORE, 3) PRICE_TARGET, and 4) AI_RPT_HEADLINE

PEPG_OUT_17 [2025-04-02 19:57:10 -0400] 676 Bytes | 167 tokens | Cum: 4626 tkns (57.83% of 8k)
==========================================================================

Finally, if more data could have improved your confidence which would you have chosen? **Choose one option:**
-> X0 <- Nothing more would have helped my analysis
-> X1 <- More stock-specific news
-> X2 <- More SEC filings (10-K, 10-Q, 8-K) Financials, risk disclosures, and business changes
-> X3 <- More SEC Insider Trading (Form 3, 4, 5) Direct buys/sells from executives and institutions
-> X4 <- Broader sector & market news
-> X5 <- Your past analysis on similar companies (specify metrics)
-> X6 <- More financial metrics
-> X7 <- Your past analysis on this exact company
-> X8 <- Something altogether different (explain...)

PEPG_IN_19 [2025-04-02 19:57:11 -0400] 126 Bytes | 29 tokens | Cum: 4755 tkns (59.44% of 8k)
==========================================================================

====================================
[2025-04-02 19:57:11] # Analysis Completed
Elapsed Time: 29.79 seconds